GlassScriptPhysician profile
Cristina E Roszel
NPI 1770707689
$3,934.46
in general payments reported to CMS, 2019-2025
30 companies · $938 in 2025
The $938 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $484 · 2023: $1,017 · 2024: $804 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,759.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $899.94 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.37 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $389.95 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $325.46 | 2021-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $244.55 | 2021-2025 | |
| Abbvie INC. | $235.66 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.36 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $158.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $141.15 | 2021-2025 | Eliquis |
| Glaxosmithkline, LLC. | $117.35 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $111.70 | 2021-2023 | |
| Seqirus USA INC | $83.17 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Gilead Sciences, INC. | $79.69 | 2021 | |
| Abbott Laboratories | $64.41 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $59.33 | 2021-2023 | Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $45.81 | 2024-2025 | Voquezna |
| Edwards Lifesciences Corporation | $44.36 | 2023-2025 | Sapien 3 Ultra Resilia |
| Axsome Therapeutics, INC. | $41.37 | 2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $32.57 | 2023 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $32.17 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.50 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $29.00 | 2023 | Prehevbrio |
| Daiichi Sankyo INC. | $22.17 | 2021 | |
| Merck Sharp & Dohme LLC | $20.65 | 2025 | Gardasil 9, Capvaxive |
| Ars Pharmaceuticals Operations, INC. | $17.64 | 2025 | Neffy |
| Eisai INC. | $15.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.39 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.08 | 2022 | |
| Verona Pharma, INC. | $14.03 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Roszel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.